The yearly changes table looks at the last quarter's/month's index values for a given year and compares it with the same quarter/month of the previous year to gauge the change in house prices during ...

Novo has a drug called CagriSema, which is a dual ingredient project product, both the GLP-1 and amylin analog, weekly injectable, potentially approvable in 2027. The next two drugs I'll hit will be ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight. Telehealth company Ro has ...

Shares of Novo Nordisk (NVO) lost value due to disappointing clinical trial results for CagriSema, the company’s latest weight-loss drug. Shares in Amazon (AMZN) contributed to performance for ...

14%). The company has faced failure to meet the weight-loss target with its CagriSema injection treatment twice, which caused Novo Nordisk a huge setback. Intense rivalry in the obesity sector ...

Novo Nordisk failed to impress the market with late-stage clinical trial data for CagriSema, an anti-obesity candidate, but it has more potential gems in its pipeline. Novo Nordisk and Eli Lilly ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

Achieving gender justice in global health—which the Lancet Commission on Gender and Global Health defines as encompassing the realisation of universal rights in relation to health equity and gender ...

Whilst the EU equivalent of National Insurance is not currently on the table, the trend has been firmly in the direction of imposing these measures on the whole bloc. The evidence for this is in the ...